DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

Fintel reports that on March 10, 2025, Lake Street downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from ...

Dust, smoke, and chemicals in the air cause about 1%-2% of lung cancers. Researchers suspect that polluted air can cause ...

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Bradley Bernstein, MD, PhD, A. Thomas Look, MD, and William R. Sellers, MD, of Dana-Farber Cancer Institute have been elected ...